1. GSK South Africa

2. “Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer” GlaxoSmithKline Mission...

3. GSK Biologicals: 2005 Global Business > £1,196 billion 2005 11% growth > 50% US and Europe Infants Infanrix Every Second: 45 doses of vaccines delivered N°1 Provider 23% world Market Share (2004)

4. GSK Biologicals: Contributing to World Health  We are a primary supplier to international organizations  We provide vaccines to developing world at preferential prices  We distributed approximately 90% of our vaccine doses to the developing world in 2006 –More than 1.5 billion doses of GSK vaccines were distributed worldwide  We work with policy-makers to establish vaccination policies and ensure vaccines are available to all

5. Worldwide Market Share of Vaccine Companies in 2005 Total Market: £ 5.2 billion Source: GSK Bio estimates based on analyst reports and company press release

6. Vaccine Development Long Lead Times and Big Investment - GSK Bio Core competencies Identify Antigens Produce Antigens Test in Animals Proof of Concept Phase IIIIFile x Registration x up to £5.5mup to £30m£250m-500m x x 3-5 yrs 2-3yrs 2-4 yrs  1 yr x Transfer Process to Manufacturing Build Facility II Research (Inc. Immunology) Preclinical Development (Inc. Formulation Science) Clinical Development (Inc Post Marketing Surveillance

7. GSK Bio Milestones - 1956-2005 1956 Killed polio vaccine (Salk™ type: injectable) 1961 Live attenuated polio vaccine (Sabin™ type: oral) 1969 Rubella vaccineWORLD FIRST 1976 Thermostable measles vaccine WORLD FIRST 1984 Varicella vaccine WORLD FIRST 1986 Recombinant hepatitis B vaccine WORLD FIRST 1992 Hepatitis A vaccine WORLD FIRST 1992 Influenza vaccine (from SSW) 1994 Acellular pertussis vaccine (DTPa)

8. 1996 Combined DTPw HBV ± HibWORLD FIRST 1996 Combined hepatitis A&B WORLD FIRST 1997 Combined DTPa/Hib and DTPa IPV WORLD FIRST 1997 Priorix 1998 Combined DTPa IPV Hib vaccine 1999 DTPa booster vaccine 2000 DTPa HBV IPV (PeNta) (EU)WORLD FIRST 2000 DTPa HBV IPV/ Hib (Hexa) 2000 Combined Hepatitis A & TyphoidWORLD FIRST 2002 DTPa HBV IPV (Pediarix) (US) 2003 Combined meningitis ACW 135 WORLD FIRST 2005Rotavirus vaccine launch in Mexico GSK Bio Milestones - 1956-2005 (cont’d)

9. Recent Launches In South Africa  Rotarix – vaccine to prevent Rota Virus GE –Launched 2006  Vaccinated about 15 000 babies so far  Prevented about 1000 hospitalizations  Infanrix Hexa –Launched January 2007 –Six vaccines in one injection  DTPa  IPV  Hib  HB

10. Pipe line  HPV Candidate Vaccine Incidence in Africa Mortality in Africa

11. HPV  The main cause of Cervical Cancer is HPV  Globally types 16, 18, 45 and 31 together account for more than 80% of Cervical Cancer cases

12. HPV  Up to 80% of women will be infected by an HPV infection at some point in their lives  Following HPV infection, your body does not always develop immunity and is therefore not protected against future infections.

13. Screening  Screening is the only way to prevent pre-cancerous lesions or the early signs of Cervical Cancer making it easier to treat successfully. However screening cannot prevent the cause of Cervical Cancer

14. Thank you